Category Archives: Biotechnology

If this vaccine fights cancer, why aren’t more people embracing it?

Share

Human Papilloma Virus

By Meredith Li-Vollmer 
Public Health – Seattle & King County

If you knew there was a vaccine that could prevent several types of cancer—including a form of cancer that kills over 250,000 women each year—would you make sure your child gets it?

Consider this:

  • An estimated 79 million Americans are infected with Human Papilloma Virus (HPV) that causes a range of cancers, as well as genital warts.
  • HPV is so common that most females and males will become infected with at least one type of HPV in their lifetime.

But there is some incredibly good news: the HPV vaccine prevents infections from HPV, and an updated HPV vaccine protects against more than twice the number of strains of HPV than the previous version.

Yes, this vaccine prevents cancer. Continue reading

Share

Google Glass in the ER? Health care moves one step closer to Star Trek

Share
Photo by Antonio Zugaldia CC.

Photo by Antonio Zugaldia CC.

By Lisa Gillespie
KHN

Imagine walking into an emergency room with an awful rash and waiting hours to see a doctor until, finally, a physician who doesn’t have specific knowledge of your condition gives you an ointment and a referral to a dermatologist.

That could change if a technological device like Google Glass, which is a wearable computer that is smaller than an ink pen and includes a camera function, could be strapped to an emergency room doctor’s head or to his or her eyeglasses and used to beam a specialist in to see patients at the bedside.

Not only would a patient get a more specific initial diagnosis and treatment, but a second visit to a dermatologist might not be necessary.

Researchers did just this for a small sample of people at the emergency room of the Rhode Island Hospital in Providence.

They found during the course of the study that 93.5 percent of patients who were seen with a skin problem liked the experience, and 96.8 percent were confident in the accuracy of the video equipment and that their privacy was protected. Continue reading

Share

Heart on a chip

Share

University of California, Berkeley researchers, led by bioengineering professor Kevin Healy, have been able to test heart drugs on human cardiac muscle cells housed in an inch-long silicone device.

The video shows cardiac muscle cells before and after exposure to isoproterenol, a drug used to treat certain heart ailments, including bradycardia (slow heart rate). It’s clear that the cells beat faster after 30 minutes of exposure to isoproterenol.The study’s lead author is Anurag Mathur.

The project is funded through the Tissue Chip for Drug Screening initiative, an interagency collaboration launched by the National Institutes of Health to develop 3-D human tissue chips that model the structure and function of human organs.

“Ultimately, these chips could replace the use of animals to screen drugs for safety,” said Healy.

Share

Safety advocate sees ‘hope and hype’ In digital revolution

Share

"Robert Wachter, MD"By Michelle Andrews
KHN

Dr. Robert Wachter is a long-time patient safety advocate who has written extensively about the trends affecting quality and safety in health care.

Wachter, associate chair of the University of California-San Francisco department of medicine, years ago coined the term “hospitalist” and predicted the rise of that profession.

In his new book, “The Digital Doctor: Hope, Hype and Harm at the Dawn of Medicine’s Computer Age,” he turns his attention to technology in health care, and the risks and rewards as we digitize everything from medical records to office visits.

We talked recently about his new book. This is an edited and condensed version of that conversation.’

Q. As I read your book I couldn’t help thinking about the elderly. Many older people aren’t tech savvy. They’re intimidated by looking up information on computers, sending email to their doctors and the like. They’re also bigger health care users than many younger people. What needs to be done to help them get and stay engaged as technology advances?

Photo: Dr. Robert Wachter by Susan Merrell/UCSF)

Continue reading

Share

More states demand notification of use of biosimilars

Share

Three red-and-white capsulesBy Michael Ollove
Stateline

Without the medicine Rachelle Crow takes for her rheumatoid arthritis, the 29-year-old Michigan woman’s face would frequently feel as if it were engulfed in flames. She would barely be able to crawl out of bed. She would have trouble opening or closing her fists or lifting her 3-year-old daughter.

Crow can do all those things thanks to Cimzia, one of a highly complex, usually expensive class of drugs known as biologics that derive from living organisms. Cimzia is recommended for women, like Crow, who are trying to get pregnant.

Notification laws require that patients and doctors are told whenever “biosimilar” imitations are substituted for brand-name biologics

.What keeps her up at night is a fear that a pharmacy could substitute a cheaper, not-quite identical drug for Cimzia without her or her doctor’s knowledge. It’s not only a return of her worst symptoms that she worries about. “If another medicine were substituted without telling me or my doctor, it could put my pregnancy at risk,” she said.

Fears like Crow’s have helped propel legislative attempts in many states this year to make sure that patients and doctors are notified whenever imitations deemed “interchangeable” by the US Food and Drug Administration (FDA) are substituted for brand-name biologics.

biosimilars

 

Already, Colorado has passed a notification law, and Utah has revised its earlier law. More than a dozen states are considering comparable measures.

Notification bills began popping up in states two years ago, but most were defeated in the face of opposition from manufacturers of biologic copies, which are called biosimilars, and from organizations representing pharmacists, who objected to the extra workload notification requirements might entail.  Continue reading

Share

No evidence Ebola in West Africa is becoming more deadly, study

Share

Ebola virusFrom the National Institutes of Health

The Ebola virus circulating in humans in West Africa is undergoing relatively few mutations, none of which suggest that it is becoming more severe or transmissible, according to a National Institutes of Health study in the journal Science.

The study compares virus sequencing data from samples taken from patients in Guinea (March 2014), Sierra Leone (June 2014) and Mali (November 2014).

Ebola virus, isolated in November 2014 from patient blood samples obtained in Mali. The virus was isolated on Vero cells in a BSL-4 suite at Rocky Mountain Laboratories.

“The Ebola virus in the ongoing West African outbreak appears to be stable—that is, it does not appear to be mutating more rapidly than viruses in previous Ebola outbreaks, and that is reassuring,” said Anthony S. Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH. “We look forward to additional information to validate this finding, because understanding and tracking Ebola virus evolution are critical to ensuring that our scientific and public health response keeps pace.” Continue reading

Share

States reluctant to regulate fertility services

Share

IVF egg thumbBy Michael Ollove
KHN

The Utah legislature took a step last week into territory where state lawmakers rarely tread.

It passed a law giving children conceived via sperm donation access to the medical histories of their biological fathers. The law itself stirred no controversy. The oddity was that the legislature ventured into the area of “assisted reproduction” at all.

Assisted reproductive technology (ART) helps infertile couples to conceive. Compared to many other industrialized nations, neither the U.S. nor state governments do much to oversee the multibillion-dollar industry.

“The United States is the Wild West of the fertility industry.”

“The United States is the Wild West of the fertility industry,” Marcy Darnovsky, executive director of the Center for Genetics and Society said, echoing a description used by many critics of the regulatory environment surrounding ART. Continue reading

Share

Do you really need counseling on your Alzheimer’s gene test?

Share

From WBUR’s CommonHealth:

A new Brigham and Women’s Hospital study finds that we may not need quite as much genetic counseling as we’d thought. Particularly on relatively cut-and-dried findings, like test results on a common gene that raises the risk of Alzheimer’s disease. Listen to WBUR host Anthony Brooks speak with Dr. Robert C. Green:

Share

Many insurers do not cover drugs approved weight-loss drugs

Share

ScaleBy Michelle Andrews
KNH

In December, the Food and Drug Administration approved a new anti-obesity drug, Saxenda, the fourth prescription drug the agency has given the green light to fight obesity since 2012.

But even though two-thirds of adults are overweight or obese — and many may need help sticking to New Year’s weight-loss resolutions — there’s a good chance their insurer won’t cover Saxenda or other anti-obesity drugs.

The health benefits of using anti-obesity drugs to lose weight—improvements in blood sugar and risk factors for heart disease, among other things—may not be immediately apparent.

“For things that are preventive in the long term, it makes plan sponsors think about their strategy,” says Dr. Steve Miller, the chief medical officer at Express Scripts, which manages the prescription drug benefits for thousands of companies. Companies with high turnover, for example, are less likely to cover the drugs, he says.

“Most health plans will cover things that have an immediate impact in that plan year,” Miller says.

Miller estimates that about a third of companies don’t cover anti-obesity drugs at all, a third cover all FDA-approved weight-loss drugs, and a third cover approved drugs, but with restrictions to limit their use. The Medicare prescription drug program specifically excludes coverage of anti-obesity drugs.

Part of the reluctance by Medicare and private insurers to cover weight-loss drugs stems from serious safety problems with diet drugs in the past, including the withdrawal in 1997 of fenfluramine, part of the fen-phen diet drug combination that was found to damage heart valves. Continue reading

Share

US provides immunity to Ebola vaccine developers

Share

 Secretary of Health & Human Services Sylvia Mathews BurwellHealth and Human Services Secretary Sylvia M. Burwell today announced a declaration under the Public Readiness and Emergency Preparedness (PREP) Act to facilitate the development and availability of experimental Ebola vaccines.

This declaration is intended to assist in the global community’s effort to help combat the current epidemic in West Africa and help prevent future outbreaks there, the HHS said.

The declaration provides immunity under United States law against legal claims related to the manufacturing, testing, development, distribution, and administration of three vaccines for Ebola virus disease. It does not, generally, provide immunity for a claim brought in a court outside the United States.

Past declarations have covered vaccines used in H5N1 pandemic influenza clinical trials in 2008, products related to the H1N1 influenza pandemic in 2009, and the development and manufacturing of antitoxins to treat botulism in 2008.

Here are more details about the action from the HHS release:

Continue reading

Share

Allen to donate $100 million to open Cell Science Institute in Seattle

Share

Paul Allen

Microsoft co-founder and philanthropist, Paul G. Allen will donate $100 million to create the Allen Institute for Cell Science in Seattle.

The Institute will be dedicated to the study of the complex living machinery of cells. The initial focus will be on how information encoded in our genes becomes three-dimensional living cells, and what goes wrong in disease?

The inaugural project, called the Allen Cell Observatory, will produce a dynamic, visual database and animated models of cell parts in action that integrate information from across the cellular and molecular sciences. The institute will make all its data, models and tools publicly available online

The Allen Institute for Cell Science will be housed in the new Allen Institute building located in Seattle’s South Lake Union neighborhood. The seven-story, 270,000 square foot building, currently under construction, will also be occupied by the Allen Institute for Brain Science. The building is scheduled for completion in the fall of 2015.

Rick Horwitz will serve as the Executive Director of the Allen Institute for Cell Science. He served for 10 years as the Director of the Cell Migration Consortium, an NIH-funded multi-institutional, multi-disciplinary collaboration for studying cell migration, and spent the past 15 years in the Department of Cell Biology, as a Harrison Distinguished Professor and University Professor, at the University of Virginia, School of Medicine, where his lab investigated the mechanisms of cell migration and dendritic spine morphogenesis.

 

Share

Are vaccinations ‘Everybody’s Business’? – documentary and discussion

Share

A community conversation sponsored by the Northwest Biomedical Research Association

Are Vaccinations ‘Everybody’s Business?’

Discussion of the locally-made documentary, “Everybody’s Business,” by Laura Green, which examines the small, tight-knit community of Vashon Island that has become a reluctant poster child for the growing debate around childhood vaccinations. This portrait of an island community digs beneath the surface to investigate the tensions between individual choices and collective responsibilities.

Tuesday night’s conversation will be facilitated by Dr. Doug Opel, Seattle Children’s Research Institute.

WHEN:
Tuesday
December 9, 2014
From 5:45pm to 7:45pm

WHERE:
Macao Chocolate+Coffee
415 Westlake Ave N.
Seattle, WA 98109

Share

More choices now available for managing your diabetes

Share

There are many options available allowing patients with diabetes to monitor and manage their glucose levels. The continuous glucose monitor (CGM) shown here includes a glucose level sensor and transmitter, a data receiver which displays the patient’s glucose levels, and an insulin delivery system. 

Screen Shot 2014-12-05 at 4.22.48 PM

FDA Consumer Update

Do you have diabetes? Do you notice that your blood glucose (sugar) levels rise or fall quickly? Has your doctor prescribed insulin to treat your diabetes? Are you comfortable with using a medical device?

If you answered yes to all of those questions, continuous glucose monitors (CGMs) and insulin pumps are tools that you and your health care professional might consider to assist you in achieving stable blood sugar levels.

Continue reading

Share

Expect to pay more out of pocket next year for speciality drugs

Share

Twenty-dollar bill in a pill bottleBy Julie Appleby
KHN

People with health coverage – including those who buy it through government insurance exchanges and Medicare beneficiaries – are likely to pay more out-of-pocket next year for so-called “specialty drugs,” which treat complex conditions, according to two studies from consulting firm Avalere Health.

More than half of the “bronze” plans now being sold to individuals through federal and state marketplaces for coverage that begins in January, for example, require payments of 30 percent or more of the cost of such drugs, Avalere said in a report out Tuesday. That’s up from 38 percent of bronze plans this year.

“…in some cases this could make it difficult for patients to afford and stay on medications,”

In “silver” level plans, the most commonly purchased exchange plans, 41 percent will require payments of 30 percent or more for specialty drugs, up from 27 percent in 2014.

As the cost of prescription medications rise, insurers are responding by requiring patients to pay a percentage of specialty drug costs, rather than a flat dollar amount, which is often far less. Insurers say the move helps slow premium increases. Continue reading

Share

Tech’s Next Challenge In Global Health: Tools, Not Apps – Forbes

Share

Earth against the black void of spaceThis month, PATH produced a new tool for diagnosing river blindness, a disease that affects nearly 18 million globally (stats that are often unheard of).  It’s the first of its kind, says Nicole Fallat, Communications Officer at PATH.

via Tech’s Next Challenge In Global Health: Tools, Not Apps.

Share